Skip to main content
SpringerLink
Log in

Antihypertensive Drug Use and The Risk of Prostate Cancer (Canada)

  • Published:
Cancer Causes & Control Aims and scope Submit manuscript

Abstract

Purpose: To verify if exposure to antihypertensive drugs was associated to prostate cancer (PC) risk.

Methods: We conducted a matched case-control study using record linkage between two population-based databases. We defined exposure as a binary variable and in terms of timing and cumulative duration of use. We controlled for detection bias and Aspirin use.

Results: Among the 2221 cases and 11,105 controls, use of any antihypertensive agent was associated with an adjusted relative risk of PC of 0.98 (CI, 0.88–1.08). Of the different classes of antihypertensives, only beta-blockers (BBs) were associated with a reduction in PC risk (OR = 0.86, CI = 0.77–0.96). In those who cumulated <1, 1–4, and ≥4 years of BB use, the risk was 0.89 (0.75–1.05), 0.91 (0.75–1.09), and 0.82 (0.69–0.96), respectively. Also, subjects with ≥4 years of alpha-blocker (ABs) use had a non-significant 25% reduction in PC risk.

Conclusions: Our results suggest that BBs and long-term use of ABs may prevent PC whereas calcium channel blockers or angiotensin-converting enzyme inhibitors do not influence PC risk.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Boyle P, Severi G (1999) Epidemiology of prostate cancer chemoprevention. Eur Urol 35: 370–376.

    Article  PubMed  Google Scholar 

  2. Brawley OW, Barnes S (2001) The epidemiology of prostate cancer in the United States. Semin Oncol Nurs 17: 72–77.

    PubMed  Google Scholar 

  3. Brawley OW, Barnes S, Parnes H (2001) The future of prostate cancer prevention. Ann NY Acad Sci 952: 145–152.

    PubMed  Google Scholar 

  4. Institut national du cancer du Canada (2002) Statistiques canadiennes sur le cancer 2002.

  5. Grossman E, Messerli FH, Goldbourt U (2002) Carcinogenicity of antihypertensive therapy. Curr Hypertens Rep 4: 195–201.

    PubMed  Google Scholar 

  6. Tamblyn R, Lavoie G, Petrella L, Monette J (1995) The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 48: 999–1009.

    Article  PubMed  Google Scholar 

  7. World Health Organization (2001) Anatomical therapeutic classi-fication (ATC) index including defined daily doses (DDD) for plain substances.

  8. Perron L, Bairati I, Moore L, Meyer F (2003) Dosage, duration and timing of nonsteroidal antiinflammatory drug use and risk of prostate cancer. Int J Cancer 106: 409–415.

    PubMed  Google Scholar 

  9. Nelson JE, Harris RE (2000) Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. Oncol Rep 7: 169–170.

    PubMed  Google Scholar 

  10. Roberts RO, Jacobson DJ, Girman CJ, Rhodes T, Lieber MM, Jacobsen SJ (2002) A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin Proc 77: 219–225.

    PubMed  Google Scholar 

  11. Benning CM, Kyprianou N (2002) Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor-independent action. Cancer Res 62: 597–602.

    PubMed  Google Scholar 

  12. Kyprianou N, Benning CM (2000) Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. Cancer Res 60:4550–4555.

    PubMed  Google Scholar 

  13. Kyprianou N, Chon J, Benning CM (2000) Effects of alpha(1)-adrenoceptor (alpha(1)-AR) antagonists on cell proliferation and apoptosis in the prostate: therapeutic implications in prostatic disease. Prostate Suppl 9: 42–46.

    Article  Google Scholar 

  14. Keledjian K, Borkowski A, Kim G, Isaacs JT, Jacobs SC, Kyprianou N (2001) Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin. Prostate 48: 71–78.

    PubMed  Google Scholar 

  15. Valeri A, Azzouzi R, Drelon E, et al. (2000) Early-onset hereditary prostate cancer is not associated with specific clinical and biological features. Prostate 45: 66–71.

    PubMed  Google Scholar 

  16. Kelloff GJ, Lieberman R, Steele VE, et al. (2001) Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer. Urology 57: 46–51.

    PubMed  Google Scholar 

  17. Grossman E, Messerli FH, Boyko V, Goldbourt U (2002) Is there an association between hypertension and cancer mortality? Am J Med 112: 479–486.

    PubMed  Google Scholar 

  18. Stumpe KO (2002) Hypertension and the risk of cancer: is there new evidence? J Hypertens 20: 565–567.

    Article  PubMed  Google Scholar 

  19. Fitzpatrick AL, Daling JR, Furberg CD, Kronmal RA, Weissfeld JL (2001) Hypertension, heart rate, use of antihypertensives, and incident prostate cancer. Ann Epidemiol 11: 534–542.

    PubMed  Google Scholar 

  20. Friedman GD (1997) Blood pressure and heart rate: no evidence for a positive association with prostate cancer. Ann Epidemiol 7: 486–489.

    PubMed  Google Scholar 

  21. Cerhan JR, Pavuk M, Wallace RB (1999) Positive association between resting pulse and cancer incidence in current and former smokers. Ann Epidemiol 9: 34–44.

    PubMed  Google Scholar 

  22. Severson RK, Nomura AM, Grove JS, Stemmermann GN (1989) A prospective analysis of physical activity and cancer. Am J Epidemiol 130: 522–529.

    PubMed  Google Scholar 

  23. Sorensen HT, Olsen JH, Mellemkjaer L, et al. (2000) Cancer risk and mortality in users of calcium channel blockers. A cohort study.Cancer 89: 165–170.

    Google Scholar 

  24. Friis S, Sorensen HT, Mellemkjaer L, et al. (2001) Angiotensinconverting enzyme inhibitors and the risk of cancer: a populationbased cohort study in Denmark. Cancer 92: 2462–2470.

    PubMed  Google Scholar 

  25. Hole DJ, Hawthorne VM, Isles CG, et al. (1993) Incidence of and mortality from cancer in hypertensive patients. BMJ 306: 609–611.

    PubMed  Google Scholar 

  26. Pahor M, Guralnik JM, Ferrucci L, et al. (1996) Calcium-channel blockade and incidence of cancer in aged populations. Lancet 348: 493–497.

    PubMed  Google Scholar 

  27. Jick H (1997) Calcium-channel blockers and risk of cancer. Lancet 349: 1699–700.

    Article  Google Scholar 

  28. Olsen JH, Sorensen HT, Friis S, et al. (1997) Cancer risk in users of calcium channel blockers. Hypertension 29: 1091–1094.

    PubMed  Google Scholar 

  29. Lever AF, Hole DJ, Gillis CR, et al. (1998) Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 352: 179–184.

    Article  PubMed  Google Scholar 

  30. Rosenberg L, Rao RS, Palmer JR, et al. (1998) Calcium channel blockers and the risk of cancer. JAMA 279: 1000–1004.

    PubMed  Google Scholar 

  31. Lindholm LH, Anderson H, Ekbom T, et al. (2001) Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomised, controlled trial. Lancet 358: 539–544.

    Article  PubMed  Google Scholar 

  32. Vezina RM, Lesko SM, Rosenberg L, Shapiro S (1998) Calcium channel blocker use and the risk of prostate cancer. Am J Hypertens 11: 1420–1425.

    Article  PubMed  Google Scholar 

  33. Gann PH, Daviglus ML, Dyer AR, Stamler J (1995) Heart rate and prostate cancer mortality: results of a prospective analysis.Cancer Epidemiol Biomarkers Prev 4: 611–616.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre de recherche en cancérologie de l'Université, Laval, Canada

    Linda Perron, Isabelle Bairati, François Harel & François Meyer

  2. Département de médecine sociale et préventive, Québec, Canada

    Linda Perron & François Meyer

Authors
  1. Linda Perron
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Isabelle Bairati
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. François Harel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. François Meyer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to François Meyer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Perron, L., Bairati, I., Harel, F. et al. Antihypertensive Drug Use and The Risk of Prostate Cancer (Canada). Cancer Causes Control 15, 535–541 (2004). https://doi.org/10.1023/B:CACO.0000036152.58271.5e

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:CACO.0000036152.58271.5e

Search

Navigation